Toxic multinodular goiter epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Toxic multinodular goiter}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References=...") |
Usama Talib (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Toxic multinodular goiter}} | {{Toxic multinodular goiter}} | ||
{{CMG}}; {{AE}} | |||
==Overview== | |||
==Epidemiology and Demographics== | |||
===Incidence=== | |||
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
===Prevalence=== | |||
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually. | |||
===Case-fatality rate=== | |||
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%. | |||
*The case-fatality rate of [disease name] is approximately [number range]. | |||
===Age=== | |||
*Patients of all age groups may develop [disease name]. | |||
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years. | |||
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age. | |||
*[Chronic disease name] is usually first diagnosed among [age group]. | |||
*[Acute disease name] commonly affects [age group]. | |||
===Race=== | |||
*There is no racial predilection to [disease name]. | |||
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | |||
===Gender=== | |||
*[Disease name] affects men and women equally. | |||
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1. | |||
===Region=== | |||
*The majority of [disease name] cases are reported in [geographical region]. | |||
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2]. | |||
===Developed Countries=== | |||
===Developing Countries=== | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{ | {{WH}} | ||
{{ | {{WS}} | ||
Revision as of 18:07, 7 August 2017
|
Toxic multinodular goiter Microchapters |
|
Differentiating Toxic multinodular goiter from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Toxic multinodular goiter epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Toxic multinodular goiter epidemiology and demographics |
|
FDA on Toxic multinodular goiter epidemiology and demographics |
|
CDC on Toxic multinodular goiter epidemiology and demographics |
|
Toxic multinodular goiter epidemiology and demographics in the news |
|
Blogs on Toxic multinodular goiter epidemiology and demographics |
|
Risk calculators and risk factors for Toxic multinodular goiter epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.
- The case-fatality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].